4-(4-Hydroxyphenyl)-2-butanone O-[2-galloyl-6-p-coumaroylglucoside]



Compound IDCDAMM00555
Common name4-(4-Hydroxyphenyl)-2-butanone O-[2-galloyl-6-p-coumaroylglucoside]
IUPAC name[4,5-dihydroxy-6-[3-(4-hydroxyphenyl)prop-2-enoyloxymethyl]-2-[4-(3-oxobutyl)phenoxy]oxan-3-yl] 3,4,5-trihydroxybenzoate
Molecular formulaC32H32O13

Experimental data

Retention time12.52
Adduct[M+H]+
Actual mz625.187
Theoretical mz625.191
Error6.68
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.3547

Identifiers and class information

Inchi keyQIEOAEKNEKYVTH-MDWZMJQENA-N
SmilesO=C(OCC1OC(OC2=CC=C(C=C2)CCC(=O)C)C(OC(=O)C3=CC(O)=C(O)C(O)=C3)C(O)C1O)C=CC4=CC=C(O)C=C4
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)6
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)18
Number of reactive functional groups (#rtvFG)4
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)624.597
Computed dipole moment(dipole)6.986
Total solvent accessible surface area (SASA)938.755
Hydrophobic component of SASA (FOSA)227.137
Hydrophilic component of SASA (FISA)412.118
Pie component of the SASA (PISA)299.5
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1795.73
Number of hydrogen bond donors (donorHB)6
Number of hydrogen bond acceptors (accptHB)14.85
Free energy of solvation of dipole (dip^2/V)0.0271778
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0387481
Globularity descriptor (glob)0.761098
Predicted polarizability in cubic angstroms (QPpolrz)57.014
Predicted hexadecane/gas partition coefficient (QPlogPC16)21.494
Predicted octanol/gas partition coefficient (QPlogPoct)37.205
Predicted water/gas partition coefficient (QPlogPw)26.263
Predicted octanol/water partition coefficient (QPlogPo/w)1.196
Predicted aqueous solubility (QPlogS)-4.764
Conformation-independent predicted aqueous solubility (CIQPlogS)-6.757
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.826
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1.224
Predicted brain/blood partition coefficient (QPlogBB)-5.264
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.352
Predicted skin permeability, log Kp (QPlogKp)-6.332
PM3 calculated ionization potential (IP(ev))9.073
PM3 calculated electron affinity (EA(eV))0.923
Number of likely metabolic reactions (#metab)8
Prediction of binding to human serum albumin (QPlogKhsa)-0.334
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)240.125
Number of nitrogen and oxygen atoms (#NandO)13
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P43166CA7Carbonic anhydrase VIIT37541SEA
P23280CA6Carbonic anhydrase VIT06569SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
P05121SERPINE1Plasminogen activator inhibitor-1T15556SEA
P60568IL2Interleukin-2T61698SEA
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SEA
P14679TYRTyrosinaseT97035SEA
O43826SLC37A4Glucose-6-phosphate translocaseT47306SEA
Q99417MYCBPMYCBP messenger RNAT37298SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T06569DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P23280CA6
T06569DI0372Seborrhoeic dermatitis[ICD-11: EA81]P23280CA6
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T15556DI0037Asthma[ICD-11: CA23]P05121SERPINE1
T15556DI0405Thrombosis[ICD-11: DB61-GB90]P05121SERPINE1
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025